---
figid: PMC7312739__ijms-21-03949-g002
figlink: pmc/articles/PMC7312739/figure/ijms-21-03949-f002/
number: Figure 2
caption: Combinatorial treatment approach of Nuclear factor-κB (NF-κB) inhibition
  and immune checkpoint blockade. Co-administration of nuclear factor κB (NF-κB) inhibitors
  and checkpoint blockade seems to be a promising approach to increase cancer patients’
  response rates. NF-κB inhibition to reduce programmed-death ligand 1 (PD-L1) expression
  on tumor cells in combination with anti-PD-1/PD-L1 antibodies could be especially
  effective to enhance anti-tumor immunity. Curcumin and celecoxib can reduce PD-L1
  levels by blocking IκB kinase (IKK) activity and consequently the NF-κB pathway
  [,]. Curcumin can also inhibit the fifth element of the COP9 signalosome (CSN5)-associated
  kinase activity leading to PD-L1 destabilization []. Blocking of oncogenic epidermal
  growth factor receptor (EGFR) signaling by EGFR-tyrosine kinase inhibitors (EGFR-TKIs)
  can attenuate NF-κB activity and reduce PD-L1 expression []. Combinatorial treatment
  of EGFR-TKIs and immune checkpoint blockade might prolong duration of response and
  prevent resistance [,]. Tumor necrosis factor α (TNFα) inhibition can reduce adverse
  events and increase efficacy of immune checkpoint blockade []. Arrows indicate paths
  to NF-κB activation, dotted arrows indicate protein translation and translocation,
  T-bars indicate inhibition.  was created with BioRender.com.
pmcid: PMC7312739
papertitle: NF-κB and Its Role in Checkpoint Control.
reftext: Annika C. Betzler, et al. Int J Mol Sci. 2020 Jun;21(11):3949.
pmc_ranked_result_index: '25272'
pathway_score: 0.9510198
filename: ijms-21-03949-g002.jpg
figtitle: Combinatorial treatment approach of Nuclear factorKB (NFKB) inhibition and
  immune checkpoint blockade
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7312739__ijms-21-03949-g002.html
  '@type': Dataset
  description: Combinatorial treatment approach of Nuclear factor-κB (NF-κB) inhibition
    and immune checkpoint blockade. Co-administration of nuclear factor κB (NF-κB)
    inhibitors and checkpoint blockade seems to be a promising approach to increase
    cancer patients’ response rates. NF-κB inhibition to reduce programmed-death ligand
    1 (PD-L1) expression on tumor cells in combination with anti-PD-1/PD-L1 antibodies
    could be especially effective to enhance anti-tumor immunity. Curcumin and celecoxib
    can reduce PD-L1 levels by blocking IκB kinase (IKK) activity and consequently
    the NF-κB pathway [,]. Curcumin can also inhibit the fifth element of the COP9
    signalosome (CSN5)-associated kinase activity leading to PD-L1 destabilization
    []. Blocking of oncogenic epidermal growth factor receptor (EGFR) signaling by
    EGFR-tyrosine kinase inhibitors (EGFR-TKIs) can attenuate NF-κB activity and reduce
    PD-L1 expression []. Combinatorial treatment of EGFR-TKIs and immune checkpoint
    blockade might prolong duration of response and prevent resistance [,]. Tumor
    necrosis factor α (TNFα) inhibition can reduce adverse events and increase efficacy
    of immune checkpoint blockade []. Arrows indicate paths to NF-κB activation, dotted
    arrows indicate protein translation and translocation, T-bars indicate inhibition.  was
    created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TLR1
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR8
  - TLR9
  - TLR2
  - TLR7
  - TLR10
  - TNF
  - IL17A
  - IFNG
  - PDCD1
  - IL17RA
  - MUC1
  - EGFR
  - IFNGR1
  - CD274
  - CHUK
  - IKBKB
  - NFKB1
  - NFKB2
  - REL
  - RELA
  - RELB
  - BCL3
  - COPS5
  - curcumin
  - celecoxib
  - tumor
genes:
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR1
  entrez: '7096'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR3
  entrez: '7098'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR5
  entrez: '7100'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR6
  entrez: '10333'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR8
  entrez: '51311'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR9
  entrez: '54106'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR2
  entrez: '7097'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR7
  entrez: '51284'
- word: TLR-/cytokine
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR10
  entrez: '81793'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR1
  entrez: '7096'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR3
  entrez: '7098'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR5
  entrez: '7100'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR6
  entrez: '10333'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR8
  entrez: '51311'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR9
  entrez: '54106'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR2
  entrez: '7097'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR7
  entrez: '51284'
- word: TLR-/cytokinereceptor
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR10
  entrez: '81793'
- word: TNFA
  symbol: TNFA
  source: hgnc_prev_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: IL-17
  symbol: IL-17
  source: hgnc_alias_symbol
  hgnc_symbol: IL17A
  entrez: '3605'
- word: IFNY
  symbol: IFNG
  source: hgnc_symbol
  hgnc_symbol: IFNG
  entrez: '3458'
- word: TNFA
  symbol: TNFA
  source: hgnc_prev_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: IL-17R
  symbol: IL17R
  source: hgnc_prev_symbol
  hgnc_symbol: IL17RA
  entrez: '23765'
- word: MUC1
  symbol: MUC1
  source: hgnc_symbol
  hgnc_symbol: MUC1
  entrez: '4582'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: IFNGR
  symbol: IFNGR
  source: hgnc_prev_symbol
  hgnc_symbol: IFNGR1
  entrez: '3459'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR1
  entrez: '7096'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR3
  entrez: '7098'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR5
  entrez: '7100'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR6
  entrez: '10333'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR8
  entrez: '51311'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR9
  entrez: '54106'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR2
  entrez: '7097'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR7
  entrez: '51284'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR10
  entrez: '81793'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: IKKA
  symbol: IKKA
  source: hgnc_alias_symbol
  hgnc_symbol: CHUK
  entrez: '1147'
- word: IKKB
  symbol: IKKB
  source: hgnc_alias_symbol
  hgnc_symbol: IKBKB
  entrez: '3551'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: Bcl3
  symbol: BCL3
  source: hgnc_symbol
  hgnc_symbol: BCL3
  entrez: '602'
- word: CSN5
  symbol: CSN5
  source: hgnc_alias_symbol
  hgnc_symbol: COPS5
  entrez: '10987'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: PD-L1)
  symbol: PDL1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: COPS5
  symbol: COPS5
  source: hgnc_symbol
  hgnc_symbol: COPS5
  entrez: '10987'
chemicals:
- word: curcumin
  source: MESH
  identifier: D003474
- word: celecoxib
  source: MESH
  identifier: C105934
diseases:
- word: tumor
  source: MESH
  identifier: D009369
---
